NCT04007107View on ClinicalTrials.gov

A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity

PHASE2CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

June 27, 2019

Primary Completion Date

July 28, 2019

Study Completion Date

September 4, 2019

Conditions
Healthy Volunteers Diabetes Mellitus, Type 2Healthy Volunteers OverweightHealthy Volunteers Obesity
Interventions
DRUG

Semaglutide (administered by DV3396 pen)

Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day

DRUG

Semaglutide (administered by PDS290 pen)

Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day

Trial Locations (1)

9728 NZ

Novo Nordisk Investigational Site, Groningen

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY